Idiopathic Short Stature, Small for Gestational Age, Turner Syndrome
Conditions
Keywords
Growth hormone, Somatotropin, Short stature, Idiopathic short stature, Small for gestational age, Turner syndrome
Brief summary
To explore the dose-response relationship between pharmacokinetics and pharmacodynamics of Y- Shaped Pegylated growth hormone injection (YPEG-GH) in children with short stature (idiopathic short stature (ISS), small for gestational age (SGA), Turner syndrome (TS)). To evaluate its tolerability, safety and efficacy and to provide evidence for dose selection and titration for future clinical development and clinical application in these population.
Interventions
DRUGYPEG-rhGH
YPEG-rhGH, 140μg/kg, s.c., once a week, for 52 weeks
DRUGrhGH
rhGH, 245μg/kg/week, divided into 7 subcutaneous injections, once daily, for 52 weeks
Sponsors
Tongji Hospital
Xiamen Amoytop Biotech Co., Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
4 Years to 11 Years
Healthy volunteers
No
Inclusion criteria
1. Prepubertal (Tanner I), aged older than 4 years and younger than10 years for girls and 11 years for boys. 2. Body weight: 12kg ≤ body weight ≤ 50kg. 3. For children with idiopathic short stature: a) Birth length and weight were at the 10th percentile and above of normal reference values for infants of the same gestational age and sex; b) Height at screening was 2.0 standard deviations (SD) below the mean height for chronological age and sex c) Exclude other causes such as systemic diseases, other endocrine diseases, nutritional diseases, chromosomal abnormalities, skeletal dysplasia, psycho-emotional disorders, etc. were excluded d) GH peak ≥10.0ng/ml confirmed by two different drug GH provocation tests; e) Bone age (BA)-chronological age (CA) ≤1 year. 4. For children with small for gestational age: a) Birth length and weight were at the 10th percentile and below the normal reference values for infants if the same gestational age and sex; b) Gestational age at birth ≥ 24 weeks; c) Height at screening was below -2 SD of the mean for the same age and sex, and please refer to the protocol annex 1 for height. 5. For children with Turner syndrome: a) Chromosome karyotype: 45, X; 45, X/46, XXqi; 45, X/46, XXr; 45, X/46, XX; 46, XXqi; 46, XXpi; 45, X/47, XXX; 46, XXp-; 45, X/46, XXp-; 46, XXq-; 45, x/46, XXq-; 45, X/46, XX/47, XXX, etc.; b) Having at least one specific physical characteristic: Including but not limited to low posterior hairline, facial skin nevus, neck flips, short neck, low ear position, small jaw, high palatal arch, shield chest, wide breast spacing, elbow ectropion, knee ectropion, short 4th and 5th metacarpal, nail dysplasia, scoliosis, ptosis, strabismus, cardiovascular system abnormalities such as aortic stenosis, bicuspid aortic valve, hypertension, and reproductive system abnormalities such as primary gonadal insufficiency, renal malformation, hypothyroidism and middle ear disease; c) The height at screening was below the mean -2SD of the same age and gender, and please refer to the protocol annex 1 for height. 6. Understands and signs the informed consent form voluntarily by the subject's parent(s) and/or legal guardian(s). And written assent of the subject is required if the subject is 8 years of age or older).
Exclusion criteria
1. For children with small for gestational: confirmed or suspected Bloom syndrome. 2. For children with Turner syndrome: containing a Y chromosome or a fragment derived from a Y chromosome. 3. Children with closed epiphysis. 4. Children who diagnosed or highly suspected growth hormone deficiency (GHD), or other types of growth abnormalities: e.g., Noonan syndrome, Prader-Willi syndrome, Russell-Silver syndrome, etc. 5. Children who have previously received systemic growth-promoting therapy, including but not limited to rhGH, aromatase inhibitors, sex hormones, etc., for at least 1 month or longer. 6. Children who are now receiving or plan to receive the therapy of glucocorticoids, methylphenidate, and any other drugs that may have an effect on growth. 7. Children with abnormal values of liver and kidney function (ALT \> 1.5 ULN, Cr \> 1 ULN). 8. Concomitant with chronic hepatitis B, AIDS, tuberculosis, and any other chronic infectious disease. 9. Patients with severe allergic constitutions or allergic to growth hormone or its excipients such as mannitol, lysine, sodium chloride and other ingredients. 10. Patients with a previous history of malignancy or are currently suffering from active malignancy, including intracranial tumors. 11. Patients with abnormal glucose regulation (including abnormal fasting glucose and/or abnormal glucose tolerance) or diabetes. 12. Patients who are mentally ill or have a family history of mental illness. 13. Patients who are suffering from chronic systemic diseases, such as malnutrition, immunocompromised individuals, asthma, etc. 14. Patients with congenital intracranial hypertension. 15. Patients with slipped capital femoral epiphysis (SCFE). 16. Patients with scoliosis exceeding 15°; 17. Patients who have participated in any drug clinical study (as a subject) within 3 months prior to screening and have received a drug intervention 18. Patients who the investigators considered unfit for the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pharmacokinetic-apparent volume of distribution | up to 52 weeks |
| Pharmacokinetic-area under plasma concentration versus time curve | up to 52 weeks |
| Pharmacokinetic-maximum serum concentration | up to 52weeks |
| Pharmacokinetic-time to reach the maximum plasma concentration | up to 52 weeks |
| Pharmacokinetic-terminal disposition phase half-life | up to 52 weeks |
| Pharmacokinetic-terminal elimination rate constant | up to 52 weeks |
| Pharmacokinetic-apparent clearance after extravascular administration | up to 52 weeks |
Secondary
| Measure | Time frame |
|---|---|
| Height velocity (HV, cm/year) | At 52 weeks of treatment |
| Change of height velocity compared to baseline (ΔHV, cm/year) | At 52 weeks of treatment |
| Height standard deviation according to chronological age (Ht SDS CA) | At 52 weeks of treatment |
| Change in bone age | At 52 weeks of treatment |
| Adverse events (including injection site reactions), changes from baseline in vital signs and laboratory tests | up to 57 weeks |
| Pharmacodynamics-the properties of Insulin-like growth facto1 and Insulin-like growth factor binding receptor 3. | up to 57 weeks |
Countries
China
Outcome results
None listed